Can a targeted drug stall lymphoma before it starts?

NCT ID NCT03282396

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase II trial tests the drug ibrutinib in 20 people with untreated, high-risk smoldering mantle cell lymphoma (MCL), a slow-growing blood cancer. The goal is to see if ibrutinib can stop the cancer from progressing by blocking enzymes that help cancer cells grow. Participants have not received any prior treatment and are monitored for safety and how long they stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib (a targeted cancer drug that blocks enzymes needed for cell growth)
What this could lead to: If successful, this could point toward a way to delay or prevent active lymphoma in people with early-stage, high-risk disease.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. Side effects from ibrutinib are possible, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.